Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P35968
UPID:
VGFR2_HUMAN
Alternative names:
Fetal liver kinase 1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1
Alternative UPACC:
P35968; A2RRS0; B5A925; C5IFA0; O60723; Q14178
Background:
Vascular endothelial growth factor receptor 2 (VEGFR-2), also known as Kinase insert domain receptor (KDR), plays a pivotal role in vascular development and angiogenesis. It acts as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, promoting endothelial cell proliferation, survival, migration, and differentiation. VEGFR-2 activation triggers multiple signaling pathways, including MAPK, AKT1, and PLCG1, essential for vascular permeability and embryonic hematopoiesis.
Therapeutic significance:
VEGFR-2 is linked to capillary infantile hemangioma, a condition marked by localized growth of capillary endothelium. Understanding VEGFR-2's role could lead to innovative treatments for angiogenesis-related diseases, offering hope for conditions characterized by abnormal blood vessel growth.